Analyst Price Target is $2.83
▲ +352.32% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Infinity Pharmaceuticals in the last 3 months. The average price target is $2.83, with a high forecast of $4.00 and a low forecast of $1.50. The average price target represents a 352.32% upside from the last price of $0.63.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Infinity Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development segment. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.